MX2023002288A - Inhibidores de la secrecion de proteinas. - Google Patents

Inhibidores de la secrecion de proteinas.

Info

Publication number
MX2023002288A
MX2023002288A MX2023002288A MX2023002288A MX2023002288A MX 2023002288 A MX2023002288 A MX 2023002288A MX 2023002288 A MX2023002288 A MX 2023002288A MX 2023002288 A MX2023002288 A MX 2023002288A MX 2023002288 A MX2023002288 A MX 2023002288A
Authority
MX
Mexico
Prior art keywords
protein secretion
secretion inhibitors
inhibitors
protein
sec61
Prior art date
Application number
MX2023002288A
Other languages
English (en)
Inventor
Dustin Mcminn
Meera Rao
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of MX2023002288A publication Critical patent/MX2023002288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente se proporcionan inhibidores de secreción, tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usarlos.
MX2023002288A 2020-08-31 2021-08-31 Inhibidores de la secrecion de proteinas. MX2023002288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072690P 2020-08-31 2020-08-31
PCT/US2021/048317 WO2022047347A1 (en) 2020-08-31 2021-08-31 Protein secretion inhibitors

Publications (1)

Publication Number Publication Date
MX2023002288A true MX2023002288A (es) 2023-03-10

Family

ID=78087485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002288A MX2023002288A (es) 2020-08-31 2021-08-31 Inhibidores de la secrecion de proteinas.

Country Status (16)

Country Link
US (1) US20230286973A1 (es)
EP (1) EP4204417A1 (es)
JP (1) JP2023539553A (es)
KR (1) KR20230058655A (es)
CN (1) CN116194455A (es)
AR (1) AR123385A1 (es)
AU (1) AU2021334388A1 (es)
BR (1) BR112023003265A2 (es)
CA (1) CA3190441A1 (es)
CL (1) CL2023000582A1 (es)
CO (1) CO2023002202A2 (es)
IL (1) IL300736A (es)
MX (1) MX2023002288A (es)
PE (1) PE20231436A1 (es)
TW (1) TW202227428A (es)
WO (1) WO2022047347A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164250A1 (en) * 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
CN113993587A (zh) * 2019-02-28 2022-01-28 科智生命科学公司 作为蛋白分泌抑制剂的噻唑衍生物

Also Published As

Publication number Publication date
BR112023003265A2 (pt) 2023-05-02
TW202227428A (zh) 2022-07-16
CO2023002202A2 (es) 2023-03-27
CN116194455A (zh) 2023-05-30
KR20230058655A (ko) 2023-05-03
IL300736A (en) 2023-04-01
CA3190441A1 (en) 2022-03-03
EP4204417A1 (en) 2023-07-05
PE20231436A1 (es) 2023-09-14
WO2022047347A1 (en) 2022-03-03
CL2023000582A1 (es) 2023-09-29
AR123385A1 (es) 2022-11-23
AU2021334388A1 (en) 2023-03-02
US20230286973A1 (en) 2023-09-14
JP2023539553A (ja) 2023-09-15

Similar Documents

Publication Publication Date Title
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
PH12021500014A1 (en) Fused ring compounds
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2021010160A (es) Preparaciones de membrana bacteriana.
MY196726A (en) Fused ring compounds
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
CR20200285A (es) Conjugados anticuerpo anti-cd40-fármaco
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
WO2019032936A8 (en) LINCONSAMIDE ANTIBIOTICS AND USES THEREOF
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2021100029A3 (en) Prodrugs of fulvestrant
MX2023002288A (es) Inhibidores de la secrecion de proteinas.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2021011754A (es) Composiciones, dispositivos y metodos para el tratamiento de la enfermedad de fabry.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same